Glyriva Bexicap Inhalation Capsule

Glycopyrronium bromide (Glycopyrrolate) Inhalation

50 mcg

Beximco Pharmaceuticals Ltd.

Pack size
Dispensing mode
Source
Agent
Retail Price	20.00 AED

Indications

Glyriva Bexicap Inhalation Capsule is used for: Maintenance bronchodilator treatment to relieve symptoms in adult patients with, chronic obstructive pulmonary disease (COPD)

Adult Dose

Inhalation Dry Powder Inhaler Capsule The recommended dosage of Glycopyrronium inhalation: One capsule once daily with the specific inhaler device at the same time of day. Nebulization One ampoule twice daily with nebuliser device. Should be administered at the same time of the day (1 ampoule in the morning and 1 ampoule in the evening).

Child Dose

Renal Dose

Administration

Contra Indications

Hypersensitivity to the active substance or to any of the excipients.

Precautions

Glycopyrronium should not be used for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy. Immediate hypersensitivity reactions may occur after administration of Glycopyrronium inhalation powder. As with other anticholinergic drugs, Glycopyrronium should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction.

Pregnancy-Lactation

Pregnancy There are no adequate and well-controlled studies in humans Animal studies have not shown teratogenicity Lactation Unknown if distributed in human breast milk Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

Interactions

Adverse Effects

Side effects of Glycopyrronium bromide (Glycopyrrolate) Inhalation : Inhaled medicines may cause inhalation-induced bronchospasm, dehydration, dry mouth, constipation, dizziness, insomnia, skin and subcutaneous tissue disorders, immune system disorders.

Mechanism of Action

Glycopyrronium is a long-acting, specific antimuscarinic agent, in clinical medicine often called an anticholinergic. It has a similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, inhibition of M3-receptors at the smooth muscle results in relaxation.

Note

Glyriva Bexicap 50 mcg Inhalation Capsule manufactured by Beximco Pharmaceuticals Ltd.. Its generic name is Glycopyrronium bromide (Glycopyrrolate) Inhalation. Glyriva Bexicap is availble in Bangladesh. Farmaco BD drug index information on Glyriva Bexicap Inhalation Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Glycopyrronium bromide (Glycopyrrolate) Inhalation :

Dry Powder Inhaler

Supotaria Convicap ^50mcg

Incepta Pharmaceuticals Ltd.

Convicap

Supotaria

Incepta Pharmaceuticals Ltd.

Inhalation Capsule

Seebri Breezhaler ^{50 mcg}

Novartis (Bangladesh) Ltd.

Inhalation Capsule

Dilgly ^{50 mcg}

UniMed UniHealth Pharmaceuticals Ltd.

Inhalation Capsule

Glycare Easycap ^{50 mcg}

Healthcare Pharmaceuticals Ltd.